The neoadjuvant Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival compared to chemotherapy alone in patients with with resectable stage IB to IIIA non-small cell lung cancer, according to a prespecified interim analysis of the phase III CheckMate -816 trial.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
